M.D. Anderson Cancer Center: Rectal Neoplasms trials

The registry lists 18 Rectal Neoplasms studies with M.D. Anderson Cancer Center as lead sponsor. 3 are open to participants now and 3 have results posted.

Early Phase 1 1Phase 1 6Phase 2 10Phase 3 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant TherapyRecruitingNCT06569368Phase 2
• Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal CancerRecruitingNCT03594630Early Phase 1
• Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerRecruitingNCT02107105
• M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite InstabilityCompletedNCT03436563Phase 1/2Results posted
• Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal CancerTerminatedNCT00745134Phase 2Results posted
• Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal CancerCompletedNCT00113230Phase 2Results posted
• A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal CancerWithdrawnNCT07223567Phase 2
• Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)WithdrawnNCT05900648Phase 2
• Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse EventsActive, not recruitingNCT05038254Not applicable
• LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal CancerActive, not recruitingNCT04616183Phase 1/2
• SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 TrialActive, not recruitingNCT04599140Phase 1/2
• Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal CancerActive, not recruitingNCT04017650Phase 1/2
• Circulating Tumor Cells in Patients With Locally Advanced Rectal CancerActive, not recruitingNCT02874885
• Young-Onset Colorectal CancerActive, not recruitingNCT02863107
• Relationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome ExpectationsActive, not recruitingNCT00648635
• Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal CancerCompletedNCT00543842Phase 1
• Proton Therapy With Capecitabine for Rectal CancerWithdrawnNCT00503932Phase 1/2
• A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal PatientsTerminatedNCT00254436Phase 3